|
Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. |
|
|
Honoraria - Amgen; Celgene; Janssen-Cilag; Novartis; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Amgen; Celgene; Janssen-Cilag; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen-Cilag |
|
|
Honoraria - Bristol-Myers Squibb; Janssen |
Travel, Accommodations, Expenses - Abbvie; Amgen; Chugai Pharma; Janssen; Takeda |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Takeda |
Research Funding - Celgene; Janssen |
|
|
|
Travel, Accommodations, Expenses - Sebia |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi; Takeda |
Speakers' Bureau - celgene; Janssen; Takeda |
|
|
Consulting or Advisory Role - Novartis |
|
|
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Pierre Fabre; Roche; Sanofi; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; CARsgen Therapeutics; Celgene; Gilead Sciences; Janssen-Cilag; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Oncopeptides; Roche; Takeda |
Travel, Accommodations, Expenses - Takeda |
|
|
Consulting or Advisory Role - Amgen; Celgene |
Research Funding - Janssen medical Affairs (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen Oncology; Takeda |
|
|
Honoraria - Amgen; Celgene; Janssen; Sanofi; Takeda |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen; Sanofi; Takeda |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Genmab; Johnson & Johnson |
|
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
|
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Celgene |